#Israel #CFO #Carmiel #Protalix #Gilad Mamlok

Protalix BioTherapeutics Appoints New CFO

In a significant organizational change, Protalix BioTherapeutics, Inc. (NYSE American: PLX), a prominent biopharmaceutical company based in Carmiel, Israel, has announced the appointment of Gilad Mamlok as its Senior Vice President and Chief Financial Officer (CFO). This strategic decision, effective from August 24, 2025, is set to reinforce the company’s growth trajectory as it continues to focus on the development and commercialization of innovative therapeutic proteins.

Transitioning Leadership

Mamlok takes over from Eyal Rubin, who has served as CFO for the past six years. To ensure a smooth transition, Mamlok has already joined the organization and is currently collaborating closely with Rubin. The latter will be available to guide the company until October 2025, providing valuable support as Mamlok steps into his new role. Dror Bashan, the President and CEO of Protalix, expressed his enthusiasm about Mamlok's vast experience in healthcare and technology, stating, "With his three decades of experience, Gilad will play a pivotal role in the execution of our growth strategy."

Mamlok’s Background

Gilad Mamlok is a seasoned finance executive with a robust background in capital markets, mergers and acquisitions, corporate governance, and investor relations. His most recent position was as CFO of TytoCare Ltd., a private company focused on remote healthcare solutions. Before that, he was with Sol-Gel Technologies Ltd., where he played an instrumental role in the company’s initial public offering. Mamlok's career also includes positions in several medical device firms such as Given Imaging, which was acquired by Covidien plc in 2014. He holds a Bachelor’s degree in Economics, graduating magna cum laude, and a Master’s in Business/Managerial Economics from Tel Aviv University.

Protalix BioTherapeutics: A Brief Overview

Protalix BioTherapeutics is recognized as a pioneer in the biopharmaceutical sector, specifically in creating recombinant therapeutic proteins through its proprietary ProCellEx® plant cell-based expression system. Notably, Protalix was the first company to gain FDA approval for a protein produced via a plant-based suspension expression system. This innovative method paves the way for industrial-scale development of recombinant proteins.

The company's flagship product, taliglucerase alfa, treats Gaucher disease and has been licensed to Pfizer for worldwide commercialization, with Protalix retaining rights in Brazil. The company’s second major product, Elfabrio®, received simultaneous approval from both the FDA and the European Medicines Agency in May 2023. Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio.

Looking ahead, Protalix's development pipeline promises a roster of proprietary versions of recombinant therapeutic proteins designed for established pharmaceutical markets, including PRX–115 for treating uncontrolled gout and PRX–119 for NETs-related diseases.

Conclusion

The appointment of Gilad Mamlok signifies a proactive approach by Protalix BioTherapeutics to strengthen its financial leadership at a crucial time in the company's growth. As Mamlok steps into his role, stakeholders will undoubtedly keep a keen eye on the strategic directions and initiatives he will bring to the table, building on the solid foundation laid by his predecessor, Eyal Rubin. Protalix remains poised for significant advancements in the ever-evolving landscape of biopharmaceuticals, continuing its mission to deliver innovative therapies to patients in need.